Journal article

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study

Abstract:: Background
The cardiovascular and kidney benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors in people with chronic kidney disease (CKD) are well established. The implementation of updated SGLT2 inhibitor guidelines and prescribing in the real-world CKD population remains largely unknown.
Methods
A cross-sectional study of adults with CKD registered with UK primary care practices in the Oxford-Royal College of General Practitioners... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Forbes, A. K., Hinton, W., Feher, M. D., Elson, W., Joy, M., Ordóñez-Mena, J. M., Fan, X., Cole, N. I., Banerjee, D., Suckling, R. J., de Lusignan, S., & Swift, P. A. (2024). Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. EClinicalMedicine, 68.

MLA Style

Forbes, AK, et al. “Implementation of Chronic Kidney Disease Guidelines for Sodium-Glucose Co-Transporter-2 Inhibitor Use in Primary Care in the UK: a Cross-Sectional Study.” EClinicalMedicine, vol. 68, 2024.

Chicago Style

Forbes, AK, W Hinton, MD Feher, et al. 2024. “Implementation of Chronic Kidney Disease Guidelines for Sodium-Glucose Co-Transporter-2 Inhibitor Use in Primary Care in the UK: a Cross-Sectional Study.” EClinicalMedicine 68.
Print

Access Document

Files:: Forbes_et_al_2024_Implementation_of_chronic.pdf

(Preview, Version of record, pdf, 782.2KB, Terms of use)

Publisher copy:: 10.1016/j.eclinm.2024.102426

Authors

+ Forbes, AK More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author

+ Hinton, W More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author
ORCID:: 0000-0003-4927-0901

+ Feher, MD More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author

+ Elson, W More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author

+ Joy, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author

More authors...

+ American Society of Nephrology More from this funder

Funder identifier:: https://ror.org/014pcm848

Publisher:: Elsevier
Journal:: EClinicalMedicine More from this journal
Volume:: 68
Article number:: 102426
Place of publication:: England
Publication date:: 2024-01-19
Acceptance date:: 2024-01-04
DOI:: 10.1016/j.eclinm.2024.102426
EISSN:: 2589-5370
ISSN:: 2589-5370
Pmid:: 38304744

Language:: English
Keywords:: chronic kidney disease

electronic health records

sodium-glucose transporter 2 inhibitors

guideline adherence

primary health care
Pubs id:: 1614837
Local pid:: pubs:1614837
Deposit date:: 2024-06-05
ARK identifier:: ark:/29072/ora_9e01ee03fb334edc9055a16169d054e6

Terms of use

Copyright holder:: Forbes et al
Copyright date:: 2024
Rights statement:: © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Licence:: CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP